Skip to content

The effects of Zn, vitamin A and magnesium supplementation on patients with hypothyroidism

The effects of Zn, vitamin A and magnesium supplementation on anthropometric parameters, metabolic, thyroid hormones, oxidative stress and hs-CRP in patients with hypothyroidism

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201709042365N17
Enrollment
88
Registered
2017-09-23
Start date
2017-10-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypothyroidism. Hypothyroidism, unspecified

Interventions

Intervention 1: Dietary Zinc supplement, 30 mg/d? Dietary vitamin A supplement, 25000 IU twice a week and Dietary magnesium supplement, 250 mg/d for 10 weeks. Intervention 2: Placebo, the same as zinc
Treatment - Other
Placebo
Dietary Zinc supplement, 30 mg/d? Dietary vitamin A supplement, 25000 IU twice a week and Dietary magnesium supplement, 250 mg/d for 10 weeks
Placebo, the same as zinc tablet as the active supplement with the same size, daily for 10 weeks? Placebo, the same as magnesium tablet as the active supplement with the same size, daily for 10 weeks

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Hypothyroid patients referring to Endocrine and Metabolism Research Institute of Iran University of Medical Sciences who have the following criteria and express their willingness to cooperate. Inclusion criteria: patients consensus; age 20 to 65 years old; BMI < 30 kg/m2; Drug therapy with levothyroxine; Exclusion Criteria: Unwillingness to continue the study; compliance below the 80 percent; having history of Diabetes; Hypertension; cardiovascular diseases; gastrointestinal diseases; anemia; pregnant or lactating women; alcohol consumer or Cigarette smoker, Taking any supplements including vitamins & minerals in last 3 months; digestive complications for supplements; Changing the dosage of the drug in the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Thyroid Hormones. Timepoint: Before intervention and 10 weeks after intervention. Method of measurement: ELIZA.

Secondary

MeasureTime frame
MDA. Timepoint: Before intervention and 10 weeks after intervention. Method of measurement: measurement kit.;Hs-CRP. Timepoint: Before intervention and10 weeks after intervention. Method of measurement: ELIZA.;Body Composition. Timepoint: Before intervention and 10 weeks after intervention. Method of measurement: Body Composition Analyser.;Basal Metabolic Rate. Timepoint: Before intervention and 10 weeks after intervention. Method of measurement: Body Composition Analyser.;TAC. Timepoint: Before intervention and 10 weeks after intervention. Method of measurement: measurement kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Reza Vafa

Iran University of Medical Sciences

vafa.m@iums.ac.ir; rezavafa@yahoo.com+98 21 8670 4743

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026